Legend Biotech Corp (LEGN) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Legend Biotech’s revenue went from $49M in fiscal 2018 to $1.0B in fiscal 2025, growth of about 54.4% a year.
Net income in fiscal 2025 was -$297M, a net margin of -28.8%; the best year in this period was 2018 with -$3M.
Over the twelve months to September 30, 2026, revenue was $1.4B and net income -$200000.
Free cash flow was -$129M in fiscal 2025 and positive in 1 of the 8 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.0B | $627M | $285M | $117M | $69M | $75M | $60M | $49M |
| Gross profit | — | $632M | $411M | $141M | $52M | $69M | $75M | — | — |
| Operating income | — | -$136M | -$310M | -$528M | -$446M | -$407M | -$308M | — | — |
| Net income | -$200000 | -$297M | -$177M | -$518M | -$446M | -$404M | -$266M | -$102M | -$3M |
| EPS (diluted) | $-0.00 | $-1.53 | $-0.91 | $-2.66 | $-2.29 | $-2.08 | $-1.37 | $-0.52 | $-0.01 |
| R&D | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +64.0% | +120.0% | +143.7% | +70.0% | −8.2% | +25.0% | +22.1% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$154M | -$100M | -$144M | -$393M | -$201M | -$198M | -$223M | -$83M | $308M |
| Capital spending | -$33M | -$29M | -$14M | -$20M | -$21M | -$42M | -$26M | -$27M | -$21M |
| Free cash flow | -$187M | -$129M | -$158M | -$413M | -$222M | -$241M | -$249M | -$110M | $287M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | — | — | — | — | — | — | — | — | — |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $902M | $287M | $1.3B | $786M | $689M | $456M | $83M | $210M |
| Debt | — | $319M | $301M | $281M | $261M | $120M | — | — | — |
| Equity | — | $1.0B | $1.0B | $1.3B | $744M | $766M | $598M | -$123M | $253M |
| Total assets | — | $1.7B | $1.7B | $1.8B | $1.3B | $1.1B | $722M | $288M | — |
| Shares (diluted) | 192M | 194M | 194M | 194M | 194M | 194M | 194M | 194M | 194M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 61.4% | 65.5% | 49.4% | 44.1% | 100.0% | 100.0% | — | — |
| Operating margin | — | -13.3% | -49.3% | -185.2% | -380.9% | -591.6% | -411.1% | — | — |
| Net margin | -0.0% | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | -355.2% | -169.4% | -5.7% |
| FCF margin | -13.8% | -12.5% | -25.2% | -145.0% | -189.9% | -349.7% | -332.4% | -183.1% | 583.6% |
| ROIC | — | -8.2% | -18.2% | -34.3% | -35.0% | -45.5% | -44.6% | — | — |
| ROE | — | -29.6% | -17.0% | -41.4% | -60.0% | -52.7% | -44.6% | 82.7% | -1.1% |
Frequently asked questions
What is Legend Biotech’s annual revenue?
$1.0B in fiscal 2025 and $1.4B over the twelve months to September 30, 2026.
How much profit does Legend Biotech make?
Net income was -$297M in fiscal 2025 (net margin -28.8%).
Is Legend Biotech’s revenue growing?
Yes: revenue rose 64.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.